Author
Xiaohua Tao
Recent research
- Health & Medicine
52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial
BACKGROUND: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To describe efficacy and safety outcomes through Week 52. METHODS: In this multicentr...